+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Healthcare Regulatory Affairs Outsourcing Market Size was valued at USD 5.2 Billion in 2022. The Healthcare Regulatory Affairs Outsourcing market Type is projected to grow from USD 5.8 Billion in 2023 to USD 11.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.60% during the forecast period (2023 - 2032). An increase in R&D activities, geographic growth by companies seeking speedy approvals in local markets, an increase in clinical trial applications, and an increase in the number of product registrations, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
In the healthcare industry, the practice of outsourcing regulatory problems has gained importance. An increase in corporate activities for geographic growth, along with their desire for speedy approvals in local markets, is predicted to have an impact on the adoption of outsourcing models for regulatory services. As a result of expanded R&D efforts, which are boosting the quantity of clinical trial applications and product registrations, the market for regulatory affairs outsourcing is expanding quickly.
Companies are under continual pressure from regulators all over the world to get clinical approvals quickly. As a result of these activities, demand for regulatory affairs services is increasing, which is promoting market growth. Regulatory affairs is a challenging field of job. The market is fueled by the growing demand to obtain approval for new products while upholding compliance and accomplishing more with fewer resources. The demand to cut costs is great for businesses in the life sciences. The use of generic medications and the demand for drugs and medical equipment at cheaper prices are anticipated to rise as a result of efforts to reduce healthcare costs.
The need for regulatory affairs outsourcing among life science firms is then expected to be boosted by rising out-of-pocket expenses, uneven economic growth, and actions taken by various governments to control the price of pharmaceuticals. In the early stages of product development, regulatory compliance and product-specific clinical advice and strategy may be essential for product approval. If regulatory compliance is not handled in the early stages of development, the approval process may be delayed as a result of inadequately conceived research, manufacturing mistakes, skipped studies, and other failures to comply with the rules. Thus, driving the Healthcare Regulatory Affairs Outsourcing market revenue.
The global Healthcare Regulatory Affairs Outsourcing market segmentation, based on Service, includes regulatory writing and publishing, regulatory submissions, clinical trial applications sand services registrations, regulatory consulting and legal representation, and other regulatory affairs. clinical trial applications sand services registrations segment dominated the global market in 2022. The rise in clinical trials worldwide, rigorous restrictions in developed countries, and advancements in legal and regulatory frameworks in developing regions like the Asia Pacific are what are driving the outsourcing trend for clinical trial applications.
The fastest forecasted growth is seen in the market for legal representation services. As a result of the pharmaceutical and medical device sectors' globalization, there is an increase in the demand for legal assistance. The laws are dynamic and incredibly complex. The altering regulatory landscape in regions like Asia Pacific, MEA, and Latin America raises the requirement for local experience for legal counsel to obtain regulatory approvals and custom clearance. These factors are increasing the demand for legal services globally.
The global Healthcare Regulatory Affairs Outsourcing market segmentation, based on End User, includes mid-size pharmaceutical companies, large pharmaceutical companies, biotechnology companies, medical device companies, and food and beverage companies. Large pharmaceutical companies segment dominated the global Healthcare Regulatory Affairs Outsourcing market in 2022. To avoid unexpected operations interruptions, large firms typically maintain long-term partnerships with their service providers. They seek a service provider that can support their diverse cross-scale and ramp-up activities while also being able to fulfill their regulatory requirements as a result. Additionally, a GEP (2020) analysis claims that large pharmaceutical companies frequently outsource about 50% of their regulatory affairs needs. These factors are promoting the growth of this market segment.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. The Asia Pacific Healthcare Regulatory Affairs Outsourcing market dominated this market in 2022 (45.80%). This is a result of the rise in clinical trials and the number of businesses attempting to penetrate developing markets like China and India. Another element that is anticipated to support the expansion of the regional market is the availability of qualified employees in the area at less expensive rates than in the United States. Moreover, In the Asia-Pacific region, the Indian Healthcare Regulatory Affairs Outsourcing market had the quickest rate of growth while China's Healthcare Regulatory Affairs Outsourcing market had the greatest market share.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
The North America Healthcare Regulatory Affairs Outsourcing Market is expected to register significant growth from 2023 to 2032. The presence of sizable pharmaceutical and medical device companies as well as the rise in R&D spending in the region are some of the key factors driving the market in North America. Due to pricing pressure brought on by the changing reimbursement landscape and generic competition as well as the rise of healthcare regulatory outsourcing services in North America, major pharmaceutical companies are outsourcing regulatory affairs tasks. Additionally, rising research and development activities and the number of clinical trials foretold the region's market expansion. Additionally, 32% of the trials were registered in the United States, with the majority of these trials being devoted to various types of medications, according to Clinicaltrials.gov's November 2021 updated data. This is likely to drive the outsourcing of regulatory affairs and, as a result, predict the market's growth. Further, In the North American area, the U.S. Healthcare Regulatory Affairs Outsourcing market had the biggest market share, while the Canada Healthcare Regulatory Affairs Outsourcing market had the quickest rate of expansion.
Europe Healthcare Regulatory Affairs Outsourcing market accounted for the healthy market share in 2022. This is brought on by the prevalence of significant players, the existence of various clinical research organizations, the rise in healthcare spending, the volume of R&D&I operations, and the expanding uptake of cutting-edge technology. Further, In the European region, the German Healthcare Regulatory Affairs Outsourcing market had the biggest market share, and the U.K. Healthcare Regulatory Affairs Outsourcing market had the quickest rate of growth.
Leading industry companies are making significant R&D investments in order to diversify their product offerings, which will drive the Healthcare Regulatory Affairs Outsourcing market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants are also engaging in a number of strategic actions to increase their global footprint. The Healthcare Regulatory Affairs Outsourcing sector needs to provide affordable products if it wants to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies employed by manufacturers in the worldwide Healthcare Regulatory Affairs Outsourcing industry to assist customers and expand the market sector is local manufacturing to reduce operational costs. Some of the biggest benefits to medicine have recently come from the Healthcare Regulatory Affairs Outsourcing sector. Major players in the Healthcare Regulatory Affairs Outsourcing market, including Accell Clinical Research, LLC, Charles River Laboratories International, Inc., Clinilabs, Inc., Criterium Inc., ICON plc, Covance, Inc., Medpace, Inc., PAREXEL International Corporation, Pharmaceutical Product Development, (PPD) LLC, Promedica International, Quintiles Transnational Corporation, and WuXi App Tec, are attempting to increase market demand by investing in research and development operations.
The contract research organization (CRO) ICON Plc (ICON) provides outsourced development services to the global biotechnology, pharmaceutical, and medical device industries. It provides specialized services that cover each phase of a product's development. The company's service portfolio covers a variety of topics, such as adaptive trials, biosimilars, clinical research services, commercialization and results, consulting, provision of functional services, medical imaging, resourcing solutions, laboratory services, strategic support, and tactical solutions for conventional, in vitro diagnostic, and software devices. The company offers research services in a variety of areas, including women's health, rare and orphan illnesses, cancer, genomics, the central nervous system, the gastrointestinal tract, medical devices, non-alcoholic steatohepatitis (NASH), and rare and genetic diseases. The headquarters of ICON are in Dublin, Ireland. In February 2021, ICON plc acquired PRA Health Sciences, Inc. for a total transaction value of $12 billion in cash and stock. As a result of this acquisition, the company's service portfolio for medical affairs has been strengthened.
Pharmacovigilance, compliance consulting, and medical information services are provided by ProPharma Group. The company offers customers in the pharmaceutical, biotechnology, and medical device industries compliance, quality assurance, and consulting services from clinical to commercialization and everywhere in between. It works closely with its customers to meet regulatory standards, corporate goals, and patient safety criteria. In August 2021, ProPharma Group acquired iSafety Systems, an Indian company. This transaction will boost ProPharma Group's position as the top provider of regulatory and compliance consulting, pharmacovigilance, clinical research services, and medical information worldwide.
· Accell Clinical Research, LLC
· Charles River Laboratories International, Inc.
· Clinilabs, Inc.
· Criterium Inc.
· ICON plc
· Covance, Inc.
· Medpace, Inc.
· PAREXEL International Corporation
· Pharmaceutical Product Development
· (PPD) LLC
· Promedica International
· Quintiles Transnational Corporation
· WuXi App Tec
April 2021: The purpose of a strategic partnership between Veeva Systems and Parexel is to quicken clinical trials through the application of innovative technology. The other company's regulatory consulting services will be beneficial to both businesses.
July 2021: GlobalCare, the world's foremost provider of patient-centric decentralized clinical trials (DCTs), was bought by Covance in order to expand its DCT solutions into international markets and meet the growing need for patient-centric trial designs.
· Regulatory Writing and Publishing
· Regulatory Submissions
· Clinical Trial Applications sand Services Registrations
· Regulatory Consulting and Legal Representation
· Other Regulatory Affairs
· Mid-Size Pharmaceutical Companies
· Large Pharmaceutical Companies
· Biotechnology Companies
· Medical Device Companies
· Food and Beverage Companies
· North America
- US
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 5.2 Billion |
|
Market Size 2023 |
USD 5.8 Billion |
|
Market Size 2032 |
USD 11.7 Billion |
|
Compound Annual Growth Rate (CAGR) |
9.60% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Service, End User, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Accell Clinical Research, LLC, Charles River Laboratories International, Inc., Clinilabs, Inc., Criterium Inc., ICON plc, Covance, Inc., Medpace, Inc., PAREXEL International Corporation, Pharmaceutical Product Development, (PPD) LLC, Promedica International, Quintiles Transnational Corporation, and WuXi App Tec |
|
Key Market Opportunities |
Economic growth in emerging market |
|
Key Market Dynamics |
An increase in geographical expansion activities by companies that aim for speedy approvals in local markets, the increase in R&D activities, and augmenting the volume of clinical trial applications and product registrations |
The global Healthcare Regulatory Affairs Outsourcing market size was valued at USD 5.2 Billion in 2022.
The global market is projected to grow at a CAGR of 9.60% during the forecast period, 2023-2032.
Asia Pacific had the largest share in the global market
The key players in the market are Accell Clinical Research, LLC, Charles River Laboratories International, Inc., Clinilabs, Inc., Criterium Inc., ICON plc, Covance, Inc., Medpace, Inc., PAREXEL International Corporation, Pharmaceutical Product Development, (PPD) LLC, Promedica International, Quintiles Transnational Corporation, and WuXi App Tec
The Clinical Trial Applications sand Services Registrations Service dominated the market in 2022.
The Large Pharmaceutical Companies End User had the largest share in the global market.
Research on the market is done by industry professionals who provide personalized insights on the industry structure, market segmentation, Type assessment, competitive landscape (CL), along with penetration, and emerging trends. In addition to years of professional experience in their various fields and sectors, their analysis is largely based on primary interview (60%) and secondary research (40%) as well as years of professional experience. In addition, our researchers forecast the market's direction over the following seven years by examining past trends and the market's current position. Additionally, various trends of segments and categories that are geographically portrayed are studied and estimated using primary and secondary research.
The key level executives (VP, CEO, Marketing Directors, and Business Development Managers) of the major industry participants who are active and prominent as well as mid-scale businesses operating in this market were interviewed in-depth for this supply-side report by overall Global Market Research.
Extensive primary research was conducted to gain a deeper grasp of the market and industry. Both primary and secondary research, as well as years of pertinent professional experience, are used to support the analysis. By analyzing past and present market patterns, our experts were able to forecast the market's course over the following seven years. For the geographically offered categories in the list of market tables, it differs per category. In connection with the Global Market research report, we also conducted a number of primary interviews with senior level executives (VP, CEO's, Directors, Marketing Directors, Business Development Managers, CFOs, Technical Consultants, Key Opinion Leaders, Industry Experts, Decision Matrix Authorities, and other crucial individuals) of the key industry players who dominated the Global market.
The primary purpose of secondary research was to gather, identify, and validate the information necessary for the thorough, technical, market-focused, and commercial analysis of the global market. With the use of this study, it was also possible to classify and segment the market in accordance with market trends, geographic markets, and regional considerations linked to market type. Analysts have gathered data in the Distribution Channel for the study of the market from reliable sources including annual reports, journals, white papers, corporate presentations, company websites, international organizations of Energy and Power manufacturers, credible paid databases, and many others to gather reliable intel.
Both top-down and bottom-up methodologies were employed to assess the accuracy of the global market size. The market for as a whole was estimated using these methods for a number of different dependent submarkets. Secondary research was used to address the major industry players, and primary and secondary research was used to calculate their market shares in the various regions. This complete intellectual process includes reading the annual and financial reports of the top market participants and conducting in-depth interviews with top industry executives (VP, CEO, Marketing Directors, and Business Development Managers) to gain important industry insights.
Through reliable secondary sources and validated primary sources, the classification of the global markets and their geographic percentage splits were established. To obtain the final qualitative and quantitative data, all relevant variables that might have an impact on the market under investigation have been taken into consideration, inspected in great depth, verified through primary research, and assessed. This information was collected, added to, and thoroughly examined by professional analysts before being provided in this report. The process used to estimate the overall market size for this study is depicted in the following image as an example.
Report Code :
RL65310
Published on :
Sep 2023
Request a Free Sample Report
Speak to Analyst